FDA Controlled Substances Staff To Focus On Early Engagement With Sponsors
Executive Summary
The new director of FDA's Controlled Substance Drug Staff, Michael Klein, wants to help sponsors find the optimal time to work with the agency on potential abuse issues surrounding their products
You may also be interested in...
The Role Of RiskMAPs: Fentora Shows Shift From Post-Market To Pre-Market
Cephalon needs to improve the risk management plan for its breakthrough cancer pain drug Fentora regardless of whether it expands use to non-cancer pain patients, according to FDA and a joint Anesthetic and Life Support Drugs and Drug Safety and Risk Management Advisory Committee
Pfizer Launches Lyrica Nine Months After First Approval
Pregabalin gestational period encompassed approval of three indications, DEA scheduling and production of packaging.
Pharma's Reform Bounce: How Big a Bounce Will $80 Bil. Buy?
Drug manufacturers made a pledge to contribute $80 bil. in a mix of savings and revenue-raising initiatives to help fund health reform. In return, they could see a wide range of new business depending on how you look at the numbers.